Since 2007, Emory Heart & Vascular Center has offered a minimally invasive treatment option for patients with aortic stenosis. The Emory Healthcare team has performed almost 2,000 Transcatheter Aortic Valve Replacement (TAVR) procedures to date, more than any other provider in the Southeast.
Emory is now among the first in the United States to offer a newly FDA-cleared device to help protect patients from the risk of stroke during TAVR procedures. The device, called the Sentinel Cerebral Protection System, is the first FDA-cleared device of its kind available in the country.
Studies have shown that during TAVR procedures, and other endovascular procedures, calcium deposits or surrounding tissue can dislodge and travel to the brain, increasing the risk of a stroke.
The Sentinel device, manufactured by Claret Medical, is designed to filter, capture and remove this debris before it reaches the brain. It has been shown to reduce strokes by 63 percent during the procedure and in the first 72 hours after it, when most strokes occur.
During the procedure, the Sentinel device is delivered percutaneously via catheter in the radial artery of the right arm before the TAVR procedure begins. The device’s two cone-shaped filters are positioned and deployed in two vessels connecting the heart to the brain – the brachiocephalic artery and the left common carotid artery – where it can begin to trap dislodged debris. After the TAVR procedure, the device and its contents are completely removed from the vessels.
Emory participated in the U.S. clinical trial, published in the Journal of American College of Cardiology, which showed that the Sentinel device captured debris in 99 percent of TAVR cases.
Emory Heart & Vascular Center’s comprehensive, cross-functional program is a one-stop destination for all types of cardiac valve and defect treatments, from medical management to traditional and minimally invasive surgical care.